Immunate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

The two proteins supplied by Immunate act together in the intrinsic coagulation pathway. Factor VIII serves as a co‑factor for factor IXa, accelerating conversion of factor X to Xa, while von Willebrand factor promotes platelet adhesion to damaged vessels and stabilizes factor VIII, together restoring effective hemostasis.

Dosing is individualized and set by the prescribing clinician. The prescriber considers the patient’s baseline factor levels, severity of bleeding, type of surgical procedure (if any), body weight, and response to previous treatments before deciding the appropriate amount and infusion schedule.

Data on the use of Immunate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and treatment decisions should be made in consultation with a specialist obstetrician‑haematologist.

To order Immunate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping options and the necessary import documentation.

Immunate contains both factor VIII and von Willebrand factor in a single preparation, which can simplify therapy for patients who need both proteins. In contrast, some alternatives provide only factor VIII or only von Willebrand factor, requiring separate products or additional dosing steps.

Immunate must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution, as these actions can degrade the protein content and affect efficacy.

Immunate is given by intravenous infusion. The healthcare professional prepares the solution according to aseptic technique, administers it through a vein over the prescribed time, and monitors the patient for any immediate infusion‑related reactions.

The most serious adverse events include severe allergic reactions such as anaphylaxis, the development of neutralizing inhibitors against factor VIII or von Willebrand factor, thromboembolic complications, and, rarely, disseminated intravascular coagulation. Prompt medical attention is required if any of these occur.

Immunate is contraindicated in individuals with a known hypersensitivity to any of its components, including plasma‑derived products. Patients with a history of severe allergic reactions to factor concentrates should avoid its use, and clinicians should assess risk before initiating therapy.